Pivotal Phase 3 early Alzheimer’s trial fully enrolled at 850 patients; 6-month database lock targeted for Q1 2027 with topline data expected then.
Parkinson’s open-label extension enrolled 266 patients toward 500; CEO Maria Maccecchini said regulatory submission preparations have begun ahead of early-2027 results.
Q2 loss widens as R&D spending rises
Annovis Bio posted a Q2 net loss of $14.82 million, widening from $6.22 million a year earlier; loss per share worsened to $0.40 from $0.32.
R&D expense more than doubled to $12.01 million, lifting total operating costs to $14.38 million from $6.27 million.
Cash and cash equivalents edged down to $18.73 million at June 30 from $19.53 million at Dec. 31, 2025.
ANVS•
